<DOC>
	<DOC>NCT00736489</DOC>
	<brief_summary>The purpose of this study is to investigate the pharmacodynamics of single doses of AZD3199 in asthmatic patients.</brief_summary>
	<brief_title>Single-dose Crossover Study to Investigate Pharmacodynamics of AZD3199</brief_title>
	<detailed_description />
	<mesh_term>Airway Obstruction</mesh_term>
	<mesh_term>AZD-3199</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Asthmatic patients with prebronchodilatory FEV1 above 60% of predicted normal and above 1.5 liters. Men and postmenopausal women above 18 years of age. Reversible airway obstruction in response to classical beta2agonist (salbutamol) Non/exsmokers Any clinically significant disease or disorder other than asthma Any clinically relevant abnormal findings at screening examinations Treatment with systemic glucocorticosteroids within the past 30 days Inhaled corticosteroid use if dosing is not kept constant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Asthma</keyword>
	<keyword>airway obstruction</keyword>
	<keyword>beta2-agonist</keyword>
	<keyword>efficacy</keyword>
	<keyword>inhalation</keyword>
</DOC>